Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.
OSP finalist
Open Knowledge
Advanced search
Action period

  1. Letter

    Action date:
    FDA Application:
    NDA207865
    Drug:
    Emend
    Active Ingredients:
    Aprepitant
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 207865 NDA APPROVAL Merck Sharp & Dohme Corp...
    • ...NDA 207865 Page 2 patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard...

  2. Label

    Action date:
    FDA Application:
    NDA207844
    Drug:
    Albenza
    Active Ingredients:
    Albendazole
    • ...HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENZA® safely and effectively. See full...
    • ...FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal...

  3. Letter

    Action date:
    FDA Application:
    NDA207844
    Drug:
    Albenza
    Active Ingredients:
    Albendazole
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 207844 NDA APPROVAL Amedra Pharmaceuticals LLC...
    • ...NDA 207844 Page 2 CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21...

  4. Summary Review

    Action date:
    FDA Application:
    NDA207844
    Drug:
    Albenza
    Active Ingredients:
    Albendazole
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207 4880rig15000 SUMMARY REVIEW...
    • ...NDA 207844. Albendazole chewable tablets Division Director Decisional Memo Date (electronic stamp) From...

  5. Label

    Action date:
    FDA Application:
    NDA207793
    Drug:
    Onivyde
    Active Ingredients:
    Irinotecan hydrochloride
    • ...HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all of the information needed to use ONIVYDE™ safely and effectively. See full...
    • ...FULL PRESCRIBING INFORMATION WARNING: SEVERE NEUTROPENIA and SEVERE DIARRHEA Fatal neutropenic sepsis occurred in 0.8% of patients receiving ONIVYDE...

  6. Letter

    Action date:
    FDA Application:
    NDA207793
    Drug:
    Onivyde
    Active Ingredients:
    Irinotecan hydrochloride
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 207793 NDA APPROVAL Merrimack Pharmaceuticals, Inc...
    • ...NDA 207793 Page 2 CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling...

  7. Label

    Action date:
    FDA Application:
    NDA207768
    Drug:
    Tuzistra xr
    Active Ingredients:
    Chlorpheniramine polistirex; codeine polistirex
    • ...HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TUZISTRA™ XR safely and effectively. See full...
    • ...12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE...

  8. Letter

    Action date:
    FDA Application:
    NDA207768
    Drug:
    Tuzistra xr
    Active Ingredients:
    Chlorpheniramine polistirex; codeine polistirex
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 207768 NDA APPROVAL Tris Pharma, Inc. 2033 Route 130...
    • ...NDA 207768 Page 2 CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21...

  9. Summary Review

    Action date:
    FDA Application:
    NDA207768
    Drug:
    Tuzistra xr
    Active Ingredients:
    Chlorpheniramine polistirex; codeine polistirex
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 2077680rig1s000 SUMMARY REVIEW...
    • ...Division Director Review NDA 207-768 Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) Extended Release Oral Suspension Summary Review...

  10. Label

    Action date:
    FDA Application:
    NDA207648
    Drug:
    Smoflipid 20%
    Active Ingredients:
    Fish oil; medium chain triglycerides; olive oil; soybean oil
    • ...-------------------------------CONTRAINDICATIONS-----------------------------• Known hypersensitivity to fish, egg, soybean, or peanut protein...
    • ...1 FULL PRESCRIBING INFORMATION WARNING: DEATH IN PRETERM INFANTS • Deaths in preterm infants after infusion of intravenous lipid emulsions have been...